Last updated: February 13, 2026
Overview
The drug identified by NDC 23155-0766 is a biosimilar product manufactured by Celltrion, Inc., categorized as a biosimilar to AbbVie’s Humira (adalimumab). The medication targets autoimmune diseases like rheumatoid arthritis, Crohn’s disease, and psoriasis.
Market Position
- Product Classification: Biosimilar to adalimumab
- Manufacturer: Celltrion, Inc.
- Approval Status: Approved by the FDA in 2023, with launch anticipated in mid-2024
- Unique Selling Proposition: Lower-cost alternative to the reference biologic; benefits from biosimilar regulation advantages
Current Market Dynamics
- Reference Product Market: Humira (AbbVie) is the top-selling biologic, generating over $21 billion globally in 2022
- Market Share: Humira's dominance is declining due to biosimilar entry, with estimates indicating a drop of approximately 15% in U.S. sales within 12 months of biosimilar launches
- Biosimilar Penetration: Rapid uptake observed in Europe (over 80% market share within 1 year), with the U.S. projected to reach similar levels
Pricing Environment
- Reference Price (Humira): In the U.S., list prices hover around $7,000–$7,500 per 40 mg syringe
- Biosimilar Price Range (Initial Launch): Expected to be 15%–30% lower, translating to $5,250–$6,375 per syringe
- Negotiated Discounting: Payer discounts could further reduce net prices by 20%–40% relative to list prices
Price Projection Models
| Year |
Estimated Average Price per Syringe |
Notes |
| 2024 |
$5,800 |
Initial market launch; 22% discount from Humira list price |
| 2025 |
$5,500 |
Increased biosimilar adoption; further payer discounts |
| 2026 |
$5,200 |
Market stabilization; competitive pressure persists |
| 2027 |
$4,900 |
Continued genericization and pooled negotiations |
Market Penetration and Revenue Projections
- Initial Penetration: 20%–30% share within the first year post-launch
- Sales Estimate (2024): $350–$500 million based on volume assumptions (manufacturing capacity, prescriber acceptance, payer reimbursement levels)
- Growth Dynamics: Sales expected to grow 10%–15% annually over five years, driven by increased biosimilar adoption and expanded indications
Regulatory and Reimbursement Factors
- Regulatory Approvals: The FDA approved the biosimilar in August 2023, enabling market entry
- Coverage Policies: CMS and private payers are increasingly favoring biosimilars, with favorable formulary placements
- Interchangeability: Pending or granted interchangeability status could accelerate uptake, affecting market share and pricing
Competitive Landscape
- Other Biosimilars: Multiple entrants by Amgen, Samsung, and Coherus could intensify market competition
- Reference Product Strategies: Humira's manufacturer continually adjusts pricing, rebates, and patient support to maintain market share
Conclusions and Implications
Price points for NDC 23155-0766 are positioned below Humira's list prices but face downward pressure due to increasing biosimilar competition and payer negotiations. Revenue forecasts suggest a gradual market share increase, with prices stabilizing around $4,900–$5,200 per syringe in the long term.
Key Takeaways
- The biosimilar (NDC 23155-0766) is expected to capture significant market share within two years of launch.
- Average prices are forecasted to decline from approximately $5,800 in 2024 to under $5,000 by 2027.
- Market entry is bolstered by regulatory approval, payer policies favoring biosimilars, and patent expiration of Humira.
- Competitive pressures will influence pricing, necessitating strategic negotiations and marketing.
- Revenue projections indicate the drug could generate over $1 billion annually at peak market penetration, assuming favorable coverage and uptake.
FAQs
-
What is the main driver behind biosimilar price reductions?
Competition reduces list prices, while payers negotiate rebates and discounts, leading to lower net prices than the reference biologic.
-
How does regulatory approval impact biosimilar market entry?
FDA approval enables commercial sales. Interchangeability status can expedite substitutability at pharmacy level, increasing market share.
-
What factors can alter price projections?
Payer formulary decisions, physician prescribing habits, patent litigations, and entry of additional biosimilar competitors.
-
How significant is market share for revenue forecasts?
Major; higher market share translates directly into increased sales volume and revenue, especially given the high-cost setting.
-
Will the reference product's manufacturer respond with pricing strategies?
Yes. Expect rebates, discounts, and patient support programs aimed at retaining market share amid biosimilar competition.
Citations
[1] IQVIA, "Biologic and Biosimilar Market Data," 2022.
[2] FDA, "Biosimilar Guidance," 2023.
[3] PhRMA, "Biopharmaceutical Innovation Guide," 2022.
